{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T06:41:17Z","timestamp":1778568077504,"version":"3.51.4"},"reference-count":87,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T00:00:00Z","timestamp":1639958400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.nucmedbio.2021.12.002","type":"journal-article","created":{"date-parts":[[2021,12,13]],"date-time":"2021-12-13T11:42:39Z","timestamp":1639395759000},"page":"10-20","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Dose estimation after a mixed field exposure: Radium-223 and intensity modulated radiotherapy"],"prefix":"10.1016","volume":"106-107","author":[{"given":"Isabella","family":"Bastiani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen J.","family":"McMahon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Turner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly M.","family":"Redmond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Conor K.","family":"McGarry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aidan","family":"Cole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joe M.","family":"O'Sullivan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin M.","family":"Prise","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liz","family":"Ainsbury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rhona","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.nucmedbio.2021.12.002_bb0005","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1200\/JCO.2003.06.100","article-title":"Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer","volume":"21","author":"Halabi","year":"2003","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.nucmedbio.2021.12.002_bb0010","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.eururo.2016.06.002","article-title":"Efficacy and safety of Radium-223 dichloride in symptomatic castration-resistant prostate cancer patients with or without baseline opioid use from the phase 3 ALSYMPCA trial","volume":"70","author":"Parker","year":"2016","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.nucmedbio.2021.12.002_bb0015","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N Engl J Med"},{"issue":"5_suppl","key":"10.1016\/j.nucmedbio.2021.12.002_bb0020","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/jco.2012.30.5_suppl.8","article-title":"Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha-pharmaceutical: results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases","volume":"30","author":"Parker","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nucmedbio.2021.12.002_bb0025","author":"Xofigo"},{"issue":"7","key":"10.1016\/j.nucmedbio.2021.12.002_bb0035","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S1470-2045(07)70147-X","article-title":"Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study","volume":"8","author":"Nilsson","year":"2007","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.nucmedbio.2021.12.002_bb0040","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.ejca.2011.12.023","article-title":"A randomized, dose\u2013response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer","volume":"48","author":"Nilsson","year":"2012","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.nucmedbio.2021.12.002_bb0045","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3390\/genes11010099","article-title":"Clustered DNA double-strand breaks: biological effects and relevance to cancer radiotherapy","volume":"11","author":"Nickoloff","year":"2020","journal-title":"Genes"},{"issue":"1","key":"10.1016\/j.nucmedbio.2021.12.002_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-54884-7","article-title":"Radiobiological effects of the alpha emitter ra-223 on tumor cells","volume":"9","author":"Bannik","year":"2019","journal-title":"Sci Rep"},{"issue":"5603","key":"10.1016\/j.nucmedbio.2021.12.002_bb0055","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/266653a0","article-title":"High-LET radiations induce a large proportion of non-rejoining DNA breaks","volume":"266","author":"Ritter","year":"1977","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.nucmedbio.2021.12.002_bb0060","doi-asserted-by":"crossref","first-page":"4451","DOI":"10.1158\/1078-0432.CCR-04-2244","article-title":"First clinical experience with \u03b1-emitting Radium-223 in the treatment of skeletal metastases","volume":"11","author":"Nilsson","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.nucmedbio.2021.12.002_bb0065","first-page":"3120","article-title":"Significant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases model","volume":"62","author":"Henriksen","year":"2002","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.nucmedbio.2021.12.002_bb0070","doi-asserted-by":"crossref","first-page":"268","DOI":"10.2967\/jnumed.112.112482","article-title":"Bone-seeking radiopharmaceuticals for treatment of osseous metastases, part 1: therapy with 223Ra-dichloride","volume":"55","author":"Pandit-Taskar","year":"2013","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.nucmedbio.2021.12.002_bb0075","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.clgc.2017.08.020","article-title":"The contemporary use of Radium-223 in metastatic castration-resistant prostate cancer","volume":"16","author":"Heinrich","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.nucmedbio.2021.12.002_bb0080","article-title":"(223)Ra targets skeletal metastases and spares normal tissue","volume":"453","author":"Kerr","year":"2002","journal-title":"Lancet Oncol"},{"issue":"1077","key":"10.1016\/j.nucmedbio.2021.12.002_bb0085","doi-asserted-by":"crossref","first-page":"20160748","DOI":"10.1259\/bjr.20160748","article-title":"Imaging and dosimetry for radium-223: the potential for personalized treatment","volume":"90","author":"Flux","year":"2017","journal-title":"Br J Radiol."},{"issue":"1","key":"10.1016\/j.nucmedbio.2021.12.002_bb0090","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00259-015-3150-2","article-title":"Dosimetry of bone metastases in targeted radionuclide therapy with alpha-emitting (223)Ra-dichloride","volume":"43","author":"Pacilio","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"10.1016\/j.nucmedbio.2021.12.002_bb0095","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00259-012-2265-y","article-title":"Dosimetry of 223Ra-chloride: dose to normal organs and tissues","volume":"40","author":"Lassmann","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"10.1016\/j.nucmedbio.2021.12.002_bb0100","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1088\/0031-9155\/57\/10\/3207","article-title":"A bone marrow toxicity model for 223Ra alpha-emitter radiopharmaceutical therapy","volume":"57","author":"Hobbs","year":"2012","journal-title":"Phys Med Biol"},{"issue":"1","key":"10.1016\/j.nucmedbio.2021.12.002_bb0105","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2967\/jnumed.119.227835","article-title":"Dose-dependent growth delay of breast cancer xenografts in the bone marrow of mice treated with 223Ra: the role of bystander effects and their potential for therapy","volume":"61","author":"Leung","year":"2020","journal-title":"J Nucl Med"},{"issue":"6","key":"10.1016\/j.nucmedbio.2021.12.002_bb0110","first-page":"404","article-title":"Targeted alpha therapy: current clinical applications","volume":"35","author":"FDC","year":"2020"},{"key":"10.1016\/j.nucmedbio.2021.12.002_bb0115","article-title":"Assessing the out-of-field dose calculation accuracy by eclipse treatment planning system in sliding window IMRT of prostate cancer patients","volume":"127","author":"Moghaddam","year":"2020","journal-title":"Comput Biol Med"},{"issue":"1","key":"10.1016\/j.nucmedbio.2021.12.002_bb0120","doi-asserted-by":"crossref","first-page":"49","DOI":"10.14735\/amko202049","article-title":"Long-term clinical results of IGRT in prostate cancer treatment","volume":"33","author":"Dole\u017eel","year":"2020","journal-title":"Klin Onkol"},{"issue":"10","key":"10.1016\/j.nucmedbio.2021.12.002_bb0125","first-page":"2803","article-title":"Hematologic toxicity of conformal radiotherapy and intensity modulated radiotherapy in prostate and bladder cancer patients","volume":"19","author":"Miszczyk","year":"2018","journal-title":"Asian Pac J Cancer Prev"},{"issue":"1","key":"10.1016\/j.nucmedbio.2021.12.002_bb0130","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.radonc.2015.11.020","article-title":"Dose-volume effects for pelvic bone marrow in predicting hematological toxicity in prostate cancer radiotherapy with pelvic node irradiation","volume":"118","author":"Sini","year":"2016","journal-title":"Radiother Oncol"},{"issue":"4","key":"10.1016\/j.nucmedbio.2021.12.002_bb0135","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.ijrobp.2011.09.015","article-title":"A comprehensive comparison of IMRT and VMAT plan quality for prostate cancer treatment","volume":"83","author":"Quan","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1007","key":"10.1016\/j.nucmedbio.2021.12.002_bb0140","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1259\/bjr\/22373346","article-title":"Volumetric modulated arc therapy: a review of current literature and clinical use in practice","volume":"84","author":"Teoh","year":"2011","journal-title":"Br J Radiol"},{"issue":"3","key":"10.1016\/j.nucmedbio.2021.12.002_bb0145","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/s00066-005-1360-4","article-title":"Dose to bone marrow using IMRT techniques in prostate cancer patients","volume":"181","author":"Gershkevitsh","year":"2005","journal-title":"Strahlenther Onkol"},{"issue":"2","key":"10.1016\/j.nucmedbio.2021.12.002_bb0150","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.meddos.2005.01.002","article-title":"IMRT versus conventional 3DCRT on prostate and normal tissue dosimetry using an endorectal balloon for prostate immobilization","volume":"30","author":"Vlachaki","year":"2005","journal-title":"Med Dosim"},{"key":"10.1016\/j.nucmedbio.2021.12.002_bb0155","series-title":"Annals of the ICRP radiological protection in medicine","year":"2007"},{"issue":"6","key":"10.1016\/j.nucmedbio.2021.12.002_bb0160","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1667\/RR15116.1","article-title":"Dicentric dose estimates for patients undergoing radiotherapy in the RTGene study to assess blood dosimetric models and the new bayesian method for gradient exposure","volume":"190","author":"Moquet","year":"2018","journal-title":"Radiat Res"},{"issue":"4","key":"10.1016\/j.nucmedbio.2021.12.002_bb0165","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.ijrobp.2019.07.022","article-title":"Compartmental model for 223Ra-dichloride in patients with metastatic bone disease from castration-resistant prostate cancer","volume":"105","author":"Taprogge","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.nucmedbio.2021.12.002_bb0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/09553002.2016.1235805","article-title":"Special issue: networking in biological and EPR\/OSL dosimetry: the european RENEB platform for emergency preparedness and research","volume":"93","author":"Kulka","year":"2017","journal-title":"Int J Radiat Biol"},{"key":"10.1016\/j.nucmedbio.2021.12.002_bb0175","series-title":"Cytogenetic dosimetry: applications in preparedness for and response to radiation emergencies","year":"2011"},{"key":"10.1016\/j.nucmedbio.2021.12.002_bb0180","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.clon.2019.02.009","article-title":"Cytogenetic biomarkers of radiation exposure","volume":"5","author":"Anderson","year":"2019","journal-title":"Clin Oncol"},{"key":"10.1016\/j.nucmedbio.2021.12.002_bb0185","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-21-0685","article-title":"Toxicity and efficacy of concurrent androgen deprivation therapy, pelvic radiotherapy, and radium-223 in patients with de novo metastatic hormone-sensitive prostate cancer","author":"Turner","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nucmedbio.2021.12.002_bb0190","doi-asserted-by":"crossref","first-page":"37","DOI":"10.6028\/jres.120.004","article-title":"Revision of the NIST standard for (223)Ra: new measurements and review of 2008 data","volume":"120","author":"Zimmerman","year":"2015","journal-title":"J Res Natl Inst Stand Technol"},{"key":"10.1016\/j.nucmedbio.2021.12.002_bb0195","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s12149-016-1093-8","article-title":"Pharmacokinetics of single dose radium-223 dichloride (BAY 88\u20138223) in japanese patients with castration-resistant prostate cancer and bone metastases","volume":"7","author":"Yoshida","year":"2016","journal-title":"Ann Nucl Med"},{"issue":"9","key":"10.1016\/j.nucmedbio.2021.12.002_bb0200","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.2967\/jnumed.115.157123","article-title":"A phase 1, open-label study of the biodistribution, pharmacokinetics, and dosimetry of 223Ra-dichloride in patients with hormone-refractory prostate cancer and skeletal metastases","volume":"56","author":"Chittenden","year":"2015","journal-title":"J Nucl Med"},{"issue":"9","key":"10.1016\/j.nucmedbio.2021.12.002_bb0205","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1007\/s00259-013-2427-6","article-title":"Phase I pharmacokinetic and biodistribution study with escalating doses of 223Ra-dichloride in men with castration-resistant metastatic prostate cancer","volume":"40","author":"Carrasquillo","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2021.12.002_bb0210","series-title":"Introduction to radiological physics and radiation dosimetry","author":"Attix","year":"2008"},{"issue":"1","key":"10.1016\/j.nucmedbio.2021.12.002_bb0215","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1038\/s41598-018-20364-7","article-title":"DNA damage in leukocytes after internal ex-vivo irradiation of blood with the \u03b1-emitter ra-223","volume":"8","author":"Schumann","year":"2018","journal-title":"Sci Rep"},{"issue":"1\u20132","key":"10.1016\/j.nucmedbio.2021.12.002_bb0225","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.mrfmmm.2005.07.007","article-title":"No increase in radiation-induced chromosome aberration complexity detected by m-FISH after culture in the presence of 5'-bromodeoxyuridine","volume":"594","author":"Sumption","year":"2006","journal-title":"Mutat Res"},{"issue":"5471","key":"10.1016\/j.nucmedbio.2021.12.002_bb0230","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/251156a0","article-title":"New giemsa method for the differential staining of sister chromatids","volume":"251","author":"Perry","year":"1974","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.nucmedbio.2021.12.002_bb0235","doi-asserted-by":"crossref","first-page":"934","DOI":"10.3109\/09553002.2013.805889","article-title":"Reduced chromosome aberration complexity in normal human bronchial epithelial cells exposed to low-LET \u03b3-rays and high-LET \u03b1-particles","volume":"89","author":"Themis","year":"2013","journal-title":"Int J Radiat Biol"},{"issue":"1","key":"10.1016\/j.nucmedbio.2021.12.002_bb0240","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/0165-1161(94)90008-6","article-title":"FISH \"painting\" patterns resulting from complex exchanges","volume":"312","author":"Savage","year":"1994","journal-title":"Mutat Res"},{"issue":"1","key":"10.1016\/j.nucmedbio.2021.12.002_bb0245","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1667\/0033-7587(2003)159[0040:TANCCA]2.0.CO;2","article-title":"Transmissible and nontransmissible complex chromosome aberrations characterized by three-color and mFISH define a biomarker of exposure to high-LET \u03b1 particles","volume":"159","author":"Anderson","year":"2003","journal-title":"Radiat Res"},{"issue":"5","key":"10.1016\/j.nucmedbio.2021.12.002_bb0250","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1667\/0033-7587(2001)155[0643:ARICCR]2.0.CO;2","article-title":"Analyzing radiation-induced complex chromosome rearrangements by combinatorial painting","volume":"155","author":"Cornforth","year":"2001","journal-title":"Radiat Res"},{"issue":"2","key":"10.1016\/j.nucmedbio.2021.12.002_bb0255","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1080\/095530098142491","article-title":"Combined use of chromosome painting and telomere detection to analyse radiation-induced chromosomal aberrations in mouse splenocytes","volume":"73","author":"Boei","year":"1998","journal-title":"Int J Radiat Biol"},{"issue":"2","key":"10.1016\/j.nucmedbio.2021.12.002_bb0260","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/oxfordjournals.rpd.a079681","article-title":"Chromosome aberrations induced in human lymphocytes by in vitro acute X and gamma radiation","volume":"15","author":"Lloyd","year":"1986","journal-title":"Radiat Prot Dosimetry"},{"issue":"2","key":"10.1016\/j.nucmedbio.2021.12.002_bb0265","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/01.HP.0000346305.84577.b4","article-title":"Dose estimation software for radiation biodosimetry","volume":"98","author":"Ainsbury","year":"2010","journal-title":"Health Phys"},{"issue":"3","key":"10.1016\/j.nucmedbio.2021.12.002_bb0270","first-page":"277","article-title":"The induction of chromosome aberrations in human lymphocytes by in vitro irradiation with \u03b1-particles from Plutonium-239","volume":"38","author":"Purrott","year":"1980","journal-title":"Int J Radiat Biol"},{"key":"10.1016\/j.nucmedbio.2021.12.002_bb0275","series-title":"International study of factors affecting human chromosome translocations","first-page":"112","volume":"652","author":"Sigurdson","year":"2008"},{"issue":"2","key":"10.1016\/j.nucmedbio.2021.12.002_bb0280","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1080\/09553000500103082","article-title":"Translocation yields in peripheral blood lymphocytes from control populations","volume":"81","author":"Whitehouse","year":"2005","journal-title":"Int J Radiat Biol"},{"issue":"1","key":"10.1016\/j.nucmedbio.2021.12.002_bb0285","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13063-019-3643-6","article-title":"CApecitabine plus Radium-223 (Xofigo\u2122) in breast cancer patients with BONe metastases (CARBON): study protocol for a phase IB\/IIA randomised controlled trial","volume":"21","author":"Coleman","year":"2020","journal-title":"Trials"},{"issue":"5","key":"10.1016\/j.nucmedbio.2021.12.002_bb0290","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1007\/s00259-018-4234-6","article-title":"Radium-223 in combination with paclitaxel in cancer patients with bone metastases: safety results from an open-label, multicenter phase ib study","volume":"46","author":"Geva","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"10.1016\/j.nucmedbio.2021.12.002_bb0295","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.clgc.2019.11.017","article-title":"Adverse events associated with Radium-223 in metastatic prostate cancer: disproportionality analysis of FDA data reflecting worldwide utilization","volume":"18","author":"Huynh-Le","year":"2020","journal-title":"Clin Genitourin Cancer"},{"issue":"5","key":"10.1016\/j.nucmedbio.2021.12.002_bb0300","article-title":"Retrospective toxicological profiling of Radium-223 dichloride for the treatment of bone metastases in prostate cancer using adverse event data","volume":"55","author":"Soldatos","year":"2019","journal-title":"Medicina (Kaunas)"},{"issue":"4","key":"10.1016\/j.nucmedbio.2021.12.002_bb0305","doi-asserted-by":"crossref","first-page":"e919","DOI":"10.1016\/j.clgc.2018.03.007","article-title":"Hematologic toxicity from Radium-223 therapy for bone metastases in castration-resistant prostate cancer: risk factors and practical considerations","volume":"16","author":"Jacene","year":"2018","journal-title":"Clin Genitourin Cancer"},{"issue":"4","key":"10.1016\/j.nucmedbio.2021.12.002_bb0310","doi-asserted-by":"crossref","first-page":"e723","DOI":"10.1016\/j.clgc.2016.11.002","article-title":"Acute myeloid leukemia after Radium-223 therapy: case report","volume":"15","author":"Varkaris","year":"2017","journal-title":"Clin Genitourin Cancer"},{"issue":"3","key":"10.1016\/j.nucmedbio.2021.12.002_bb0315","doi-asserted-by":"crossref","first-page":"e501","DOI":"10.1016\/j.clgc.2016.12.028","article-title":"Acute promyelocytic leukemia after treatment of metastatic castration-resistant prostate cancer with Radium-223","volume":"15","author":"Odo","year":"2017","journal-title":"Clin Genitourin Cancer"},{"issue":"5","key":"10.1016\/j.nucmedbio.2021.12.002_bb0320","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jnci\/djv380","article-title":"Whole-body and microenvironmental localization of Radium-223 in Na\u00efve and mouse models of prostate cancer metastasis","volume":"108","author":"Abou","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.nucmedbio.2021.12.002_bb0325","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00411-005-0275-x","article-title":"Chromosomal aberrations in peripheral lymphocytes of patients treated with radium-224 for ankylosing spondylitis","volume":"44","author":"Stephan","year":"2005","journal-title":"Radiat Environ Biophys"},{"issue":"9","key":"10.1016\/j.nucmedbio.2021.12.002_bb0330","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1007\/s00259-020-05170-6","article-title":"\u03b1-particle-induced DNA damage tracks in peripheral blood mononuclear cells of [223Ra]RaCl2-treated prostate cancer patients","volume":"48","author":"Schumann","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2021.12.002_bb0335","series-title":"Age-dependent doses to members of the public from intake of radionuclides - part 2 ingestion dose coefficients","first-page":"3","volume":"23","author":"ICRP","year":"1993"},{"issue":"4","key":"10.1016\/j.nucmedbio.2021.12.002_bb0340","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1177\/0267659114547250","article-title":"Blood volume measurement by hemodilution: association with valve disease and re-evaluation of the Allen formula","volume":"30","author":"Hilberath","year":"2015","journal-title":"Perfusion"},{"key":"10.1016\/j.nucmedbio.2021.12.002_bb0345","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1146\/annurev-fluid-122316-045259","article-title":"Lymphatic system flows","volume":"50","author":"Moore","year":"2018","journal-title":"Annu Rev Fluid Mech"},{"key":"10.1016\/j.nucmedbio.2021.12.002_bb0350","doi-asserted-by":"crossref","DOI":"10.1088\/1742-6596\/444\/1\/012006","article-title":"Accuracy required and achievable in radiotherapy dosimetry: have modern technology and techniques changed our views?","volume":"444","author":"Thwaites","year":"2013","journal-title":"J Phys Conf Ser"},{"issue":"4","key":"10.1016\/j.nucmedbio.2021.12.002_bb0355","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/PPO.0000000000000138","article-title":"The contribution of angiogenesis to the process of metastasis","volume":"21","author":"Bielenberg","year":"2015","journal-title":"Cancer J"},{"issue":"15","key":"10.1016\/j.nucmedbio.2021.12.002_bb0360","doi-asserted-by":"crossref","first-page":"5396","DOI":"10.1158\/1078-0432.CCR-04-2420","article-title":"Angiogenesis in the bone marrow of patients with breast cancer","volume":"11","author":"Chavez-MacGregor","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.nucmedbio.2021.12.002_bb0365","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nrc867","article-title":"Metastasis to bone: causes, consequences and therapeutic opportunities","volume":"2","author":"Mundy","year":"2002","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"10.1016\/j.nucmedbio.2021.12.002_bb0370","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1667\/RR0813.1","article-title":"Effect of linear energy transfer (LET) on the complexity of \u03b1-particle-induced chromosome aberrations in human CD34+ cells","volume":"167","author":"Anderson","year":"2007","journal-title":"Radiat Res"},{"issue":"1","key":"10.1016\/j.nucmedbio.2021.12.002_bb0375","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/0165-1161(94)90008-6","article-title":"Fish \u201cpainting\u201d patterns resulting from complex exchanges","volume":"312","author":"Savage","year":"1994","journal-title":"Mutat Res"},{"issue":"1","key":"10.1016\/j.nucmedbio.2021.12.002_bb0380","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/0027-5107(94)90308-5","article-title":"On the scoring of FISH-\u201cpainted\u201d chromosome-type exchange aberrations","volume":"307","author":"Savage","year":"1994","journal-title":"Mutat Res Fundam Mol Mech Mutagen"},{"issue":"2","key":"10.1016\/j.nucmedbio.2021.12.002_bb0385","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/09553002310001655430","article-title":"Effect of americium-241 \u03b1-particles on the dose\u2013response of chromosome aberrations in human lymphocytes analysed by fluorescence in situ hybridization","volume":"80","author":"Barquinero","year":"2004","journal-title":"Int J Radiat Biol"},{"issue":"3","key":"10.1016\/j.nucmedbio.2021.12.002_bb0390","first-page":"549","article-title":"Lymphocyte chromosomal aberrations and their complexity induced in vitro by plutonium-239 alpha-particles and detected by FISH","volume":"47","author":"Moquet","year":"2001","journal-title":"Cell Mol Biol (Noisy-le-Grand)"},{"issue":"1","key":"10.1016\/j.nucmedbio.2021.12.002_bb0395","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/095530000138989","article-title":"Complex chromosome aberrations in peripheral blood lymphocytes as a potential biomarker of exposure to high-LET alpha-particles","volume":"76","author":"Anderson","year":"2000","journal-title":"Int J Radiat Biol"},{"issue":"4","key":"10.1016\/j.nucmedbio.2021.12.002_bb0400","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1080\/095530097143194","article-title":"Chromosomal aberrations induced in human lymphocytes by high-LET irradiation","volume":"72","author":"Testard","year":"1997","journal-title":"Int J Radiat Biol"},{"issue":"4","key":"10.1016\/j.nucmedbio.2021.12.002_bb0405","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1080\/09553009514550491","article-title":"Frequencies of complex chromosome exchange aberrations induced by 238Pu \u03b1-particles and detected by fluorescence in situ hybridization using single chromosome-specific probes","volume":"67","author":"Griffin","year":"1995","journal-title":"Int J Radiat Biol"},{"issue":"1","key":"10.1016\/j.nucmedbio.2021.12.002_bb0410","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1667\/RR3089.1","article-title":"Chromosome damage in human cells by \u03b3 rays, \u03b1 particles and heavy ions: track interactions in basic dose-response relationships","volume":"179","author":"Loucas","year":"2013","journal-title":"Radiat Res"},{"issue":"5","key":"10.1016\/j.nucmedbio.2021.12.002_bb0415","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1667\/0033-7587(2001)155[0660:CCEIBG]2.0.CO;2","article-title":"Complex chromosome exchanges induced by gamma rays in human lymphocytes: an mFISH study","volume":"155","author":"Loucas","year":"2001","journal-title":"Radiat Res"},{"issue":"2","key":"10.1016\/j.nucmedbio.2021.12.002_bb0420","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.radonc.2013.09.021","article-title":"Chromosome inversions in lymphocytes of prostate cancer patients treated with X-rays and carbon ions","volume":"109","author":"Pignalosa","year":"2013","journal-title":"Radiother Oncol"},{"issue":"1","key":"10.1016\/j.nucmedbio.2021.12.002_bb0425","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.radonc.2009.08.031","article-title":"Chromosomal aberrations in peripheral blood lymphocytes of prostate cancer patients treated with IMRT and carbon ions","volume":"95","author":"Hartel","year":"2009","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.nucmedbio.2021.12.002_bb0430","doi-asserted-by":"crossref","DOI":"10.1186\/s13014-019-1223-2","article-title":"Leukotoxicity after moderately hypofractionated radiotherapy versus conventionally fractionated dose escalated radiotherapy for localized prostate cancer: a secondary analysis from a randomized study","volume":"14","author":"Sanguineti","year":"2019","journal-title":"Radiat Oncol"},{"issue":"3","key":"10.1016\/j.nucmedbio.2021.12.002_bb0435","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.ejmp.2016.03.003","article-title":"Predicting toxicity in radiotherapy for prostate cancer","volume":"32","author":"Landoni","year":"2016","journal-title":"Phys Med"},{"issue":"5","key":"10.1016\/j.nucmedbio.2021.12.002_bb0440","doi-asserted-by":"crossref","first-page":"835","DOI":"10.2217\/fon.13.237","article-title":"Hematologic changes during prostate cancer radiation therapy are dependent on the treatment volume","volume":"10","author":"Pinkawa","year":"2014","journal-title":"Future Oncol"},{"key":"10.1016\/j.nucmedbio.2021.12.002_bb0445","doi-asserted-by":"crossref","DOI":"10.1158\/1541-7786.MCR-21-0005","article-title":"Radium-223-induced bystander effects cause DNA damage and apoptosis in disseminated tumor cells in bone marrow","author":"Canter","year":"2021","journal-title":"Mol Cancer Res"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096980512100531X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096980512100531X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T04:29:38Z","timestamp":1760848178000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S096980512100531X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":87,"alternative-id":["S096980512100531X"],"URL":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2021.12.002","relation":{},"ISSN":["0969-8051"],"issn-type":[{"value":"0969-8051","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dose estimation after a mixed field exposure: Radium-223 and intensity modulated radiotherapy","name":"articletitle","label":"Article Title"},{"value":"Nuclear Medicine and Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2021.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2021 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}